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Abbreviations: 
 
Apaf-1          apoptotic protease activation factor-1 
APC              antigen-presenting cells 
DM  differentiation medium 
DMD  Duchenne muscular dystrophy 
FGF               fibroblast growth factor 
GM  growth medium 
HGF              hepatocyte growth factor 
HS                 heat shock  
HSP               heat shock proteins 
IGF-1            insuline growth factor-1 
IL-6               Interleukin-6 
MPC  myogenic precursor cell 
MRF             myocyte regulator factor 
MT  myoblast transplantation 
SC                  satellite cells 
TNF               tumor necrosis factor  
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Introduction ( en français) 
 
La transplantation de myoblaste est une thérapie cellulaire largement étudiée pour son 
potentiel dans le traitement des lésions musculaires, des défaillances cardiaques et des 
myopathies héréditaires comme la Dystrophie Musculaire de Duchenne (DMD). La DMD 
touche environ un garçon sur 3500 naissances et est caractérisée par l'absence de dystrophine. 
Cette protéine joue un rôle important dans le maintient de la stabilité et de l'intégrité 
musculaire; son absence entraîne une dégénérescence progressive et irréversible du muscle 
squelettique. 
 
Les myoblastes, dans le muscle postnatal, sont considérés comme dérivant de cellules 
situées à la surface des myofibrilles, sous la membrane basale. Du fait de leur localisation, ces 
cellules sont appelées "cellules satellites" (CS). Les CS sont activées en réponse à de 
nombreux stimuli, incluant l'exercice, la lésion ou le stretching. Les CS alors activées, re-
entrent dans le cycle cellulaire pour donner naissance aux myoblastes, qui vont effectuer de 
nombreux cycles de prolifération avant la différentiation finale et la fusion avec des 
myofibrilles naissantes et/ou existantes. 
Les myoblastes (d'origine murins, porcins, humains…) peuvent être isolés et amplifiés in 
vitro à partir de biopsie de muscle squelettique. Après prolifération, les myoblastes peuvent 
aussi êtres transplantés à des fins thérapeutiques. Les résultats obtenus lors d'études cliniques 
mettent en évidence la brèche qu'il subsiste entre les conditions expérimentales utilisées chez 
la souris et la réalité thérapeutique chez l'homme. Ces données soulignent la nécessité de 
disposer de modèles animaux pré cliniques pour l'étude de la transplantation de myoblaste. 
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Notre laboratoire à Genève a récemment démontré que le cochon représentait un modèle 
approprié pour explorer les différentes stratégies de transplantation de myoblastes applicables 
chez l'homme. Cependant, ces approches sont limitées par une importante mort cellulaire 
post-injection, un obstacle majeur à surmonter. 
Afin de mieux comprendre les phénomènes de mort cellulaire après la transplantation de 
myoblastes, l'analyse peut être divisée en deux périodes: l'analyse de la survie précoce (c.a.d., 
durant les heures ou jours immédiatement après l'injection) et l'analyse de la survie à long 
terme (c.a.d, durant la période nécessaire pour un possible bénéfice clinique, qui serait 
idéalement de durée indéfinie). Il existe toujours des discordances dans l'interprétation des 
résultats, que ce soit à court terme ou à long terme après la transplantation. Ceci peut être 
notamment expliqué par deux facteurs: les méthodes utilisées pour la détection des 
myoblastes du donneur après injection ainsi que la définition des standards utilisés pour 
définir le point de référence des 100% de survie des cellules.  
De nombreux facteurs sont impliqués dans la mort cellulaire post-injection, comme les 
tensions physiques provoquant ainsi une inflammation non spécifique. Néanmoins, les 
facteurs comme l'apoptose, la nécrose ainsi que l'exposition des myoblastes aux conditions de 
culture sont les causes majeurs de la mort cellulaire. De nombreuses méthodes ont été 
développées afin de réduire la mort cellulaire. Récemment, des études chez la souris ont 
démontré que les protéines induites par un  choc thermique (spécialement HSP 70) peuvent 
protéger les myoblastes du donneur et ainsi accroître leur survie après la transplantation. 
Les protéines de choc thermique (HSP) sont exprimées dans tous les types cellulaires et 
jouent un rôle important dans la physiologie de la cellule. Le rôle cytoprotecteur des HSP, 
notamment HSP70, a été extensivement étudié in vitro mais aussi in vivo, dans de 
nombreuses maladies.  
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Dans cette étude, nous avons pour but de déterminer: (1) si un choc thermique à 42°C 
peut induire une surexpression d'HSP70 sur des myoblastes porcins; (2) si ce choc thermique 
modifie les propriétés myogéniques des myoblastes porcins; (3) si la surexpression d'HSP70 
accroît la survie des myoblastes après transplantation autologue dans le muscle squelettique. 
Nous avons démontré que le choc thermique pré-transplantation augmente de façon 
significative l'expression d'HSP70 sur des myoblastes porcins et que ce traitement prolonge la 
survie des myoblastes après injection dans le muscle intact. Cette technique représente un 
moyen simple et efficace pour accroître la survie des myoblastes après transplantation, et peut 
représenter un traitement potentiel afin d'améliorer le transfert de myoblastes chez les 
patients. 
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Abstract    
Background  Myoblast transplantation (MT) represents a potential treatment for Duchenne 
muscular dystrophy (DMD), cardiac failure and muscle trauma.  The rapid and massive death 
of  transplanted cells after MT is considered as a major hurdle, which limits the efficacy of 
MT treatment.  Heat shock proteins (HSP), are overexpressed  when cells undergo various 
types of stresses. HSP have been described to protect cells in vivo and in vitro against  diverse  
insults. The aim of our study is to investigate whether HSP overexpression could increase 
myoblast survival after auto-transplantation in pig intact skeletal muscle. 
Methods   HSP expression was induced by warming the cells at 42°C for 1 hour.  HSP 
expression was quantified by western blot and flow cytometry  24 hours after the stress. To 
investigate the myogenic characteristics of myoblasts, desmin and CD56 were analysed by 
western blot and flow cytometry,   and the fusion index was measured.  We also quantify cell 
survival after autologous transplantation in pig intact skeletal muscle and follow cell 
integration. 
Results    Heat shock treatment of myoblsats induce a significative overexpression of  HSP70 
(P< 0.01) without loss of their myogenic characteristics as assessed by FACS and fusion 
index.  In vivo (n=7), the myoblast survival rate were not significantly different at 24 h 
between HS treated and non-treated cells (67.7 ± 8.35 % versus 52.9 ± 10.82 %). However, 
the myoblast survival rate in the heat shocked cells increased  by  twofold at 48 h (52.3 
 ± 8.22 % versus 22.0 ± 5.90 %) and  more than threefold at 120 h (26.3 ± 5.54 % versus 8.7 
± 3.34 %). Histological analysis showed the presence of non-heat shocked donor myoblasts 
that fused with host myotubes.  
Conclusion   HS pre-treatment increased HSP70 expression in porcine myoblasts, and 
improved the survival rate after autologous transplantation.  Therefore, HS pre-treatment of 
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MPC in vitro is a simple and effective way to enhance cell survival after  transplantation in 
pig. It may represent a potential method to overcome the limitations of MT treatment. 
 
Introduction 
      Myoblast transplantation (MT) is a widely investigated cell therapy technique for the 
treatment of  Duchenne muscular dystrophy (DMD)[1,2], cardiac failure[3,4] and severe muscle 
injuries[5]. 
      DMD, arising from mutations in the X-linked dystrophin gene, is the most common 
inherited myopathy characterized by the absence of dystrophin[1,2]. Dystrophin is a rod-like 
cytoskeletal protein, which is found at the inner surface of muscle fibers. The lack of 
dystrophin, which plays a key role in maintaining the muscle cell membrane integrity and 
stability, leads skeletal muscle to degenerate progressively and irreversibly. Thereby, DMD is 
clinically expressed by a progressive  paresis in the childhood, leading to paralysis in the 
adolescence, with death usually resulting in the third decade from cardiopulmonary problems. 
The incidence of the disease is 1 DMD per approximately 3500 live male births, irrespective 
of race or nationality[6]. Due to the severity and relative frequency of the disease, DMD 
became the most studied skeletal muscle illness in recent years. Myoblast transplantation 
(MT) is currently one of the most important method in cell transplantation therapy to DMD. 
      MT is also considered as a new treatment to improve the survival of patients with cardiac 
failure. MT treatment to these diseases has shown some success in animal experiments and in 
the clinic. However, the development of MT is still limited by the rapid death of most of  the 
donor cells. To decrease the death of donor cells, several method (e.g., irradiation and 
cytokine ) have been used. Recent studies[7,8,9,10] showed that heat shock proteins (HSP, 
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especially HSP70), which were induced by heat shock treatment, could protect the donor cells 
and improve their survival after transplantation. Accordingly, we hypothesized that HS 
treatment of myogenic precursor cells ( MPC ) should improve their survival after autologous 
transplantation into the skeletal muscle.  We have developed an experimental animal in pig, 
because pig is a suitable large animal model for human biomedical research as their organs 
and tissues are similar in size and function to adult humans. 
 
1. Skeletal muscle development   
     Skeletal muscle consists of postmitotic multinucleated muscle fibres.   Not all myoblasts 
fuse into myotubes, some remain quiescent cells. Those are the satellite cells. The daughter 
cells of activated satellite cells (called myogenic precursor cells, MPC), proliferate in 
response to the increase of local mitogens, such as fibroblast growth factor (FGF) family 
members. Under the influence of growth factors, myoblasts withdraw irreversibly from the 
cell cycle and fuse to form multinucleated myotubes. Myotubes undergo progressive 
maturation and hypertrophy to form differentiated myofibers characteristic of adult skeletal 
muscle.  
 
2. Satellite Cells 
 
2.1 Definition, Characteristics, and Role  
      Myoblast in postnatal muscle are classically considered to be derived from cells located 
on the surface of the myofiber and lying beneath the basement membrane, but separated from 
the muscle fibre itself. In adult muscle, the quiescent mononucleated myoblasts were 
originally defined on the basis of their localisation, hence the term “satellite cells (SC)”.   SC 
are considered to form a stable, self-renewing pool of stem cells in adult muscle. They play a 
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major role in tissue growth, repair, and hypertrophy. Two recent studies reported that satellite 
cells are not the only source of myoblasts in the skeletal muscle, the other being muscle side 
population (SP) cells[11,12]. However, it has been confirmed that satellite cells alone are 
sufficient to regenerate a myofiber[13].  
     Self-renewal of SC is a necessary process without which recurrent muscle regeneration 
would rapidly lead to the depletion of satellite cell pool. Schultz[14] demonstrated that there 
were two satellite cell populations in the growing rat muscle. One population, respresenting 
80% of the SC, divided rapidly and was responsible for providing myonuclei to the growing 
fibre. The other population, called “reserve cells”, divided at a slower rate and was suggested 
to replenish the SC pool. Likewise in mice, the small “subpopulation”, which has the ability 
of self-renewing, can maintain a minimal cell size and remain relatively quiescent until 
surrounding cell-density become extremely low[11], at which time they reenter the cell cycle 
and become larger, presumably due to the increase in protein accretion associated with 
activity[15]. These observations are consistent with the idea that a small proportion of satellite 
cells that has undergone proliferation returns to the quiescent state, thereby repopulating the 
SC pool[14,16,17]. The two populations of myoblast have different fate after transplantation. 
Beauchamp et al[16]  reported that all  donor-derived muscle cells is produced from a minority 
of small cell population that survive and proliferate rapidly in vivo under conditions in which 
the majority of large cells undergo rapid death.  
     SC are present in all skeletal muscles, but their density differs in various muscle. The 
percentage of SC in the adult slow soleus muscle is twofold higher than that in the adult fast 
extensor digitorum longus muscles, and higher numbers of satellite cells are found associated 
with slow muscle fibers as compared with fast fibers within the same muscle[18].  
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2.2 Activation, Proliferation and Differentiation  
      In the course of muscle regeneration, quiescent SC are activated and start to  proliferate. 
After several rounds of proliferation, SC differentiate and fuse to form new myofibers or to 
repair damaged one. The promotion of SC activation, proliferation, and differentiation could 
be implicated by several signals and growth factors[12,15,19,20,21]( Figure 1). For example, the 
Notch signaling pathway, which is an evolutionarily conserved mechanism that regulates the 
determination of cell fate during the development of various tissues and organ[19], and is 
activated upon muscle injury, regulates satellite cells transition from quiescence to 
proliferation in single fiber cultures, thereby expanding the myoblast population in injured 
muscle[19]. Hepatocyte growth factor (HGF), together with its receptor, c-met, is a known 
activator of satellite cells[20]. In addition to HGF, other molecules are also involved in the 
activation or expansion of SC during regeneration, including FGF-2, FGF-6, interleukin-6( 
IL-6 ), and insuline growth factor-1( IGF-1) [21]. 
      Gene and protein expressions during the process of activation, proliferation, and 
differentiation of SC remain to be elucidated. Quiescent SC express c-met; M-cadherin, ( a 
calcium-dependent cell adhesion molecule ); Pax-7, ( a paired box transcription factor ), and 
CD34[16,17,21,22]. Activation of SC is characterized by the rapid upregulation of MyoD and 
Myf-5[21,22]. In general, quiescent SC do not have any detectable levels of myocyte regulatory 
factor (MRFs). Activated SC enter the cell cycle and become myoblast, then first express 
either MyoD or Myf5 followed soon after by co-expression of MyoD and Myf-5[21,23]. 
Proliferating myoblasts, express Desmin, MyoD, Myf5, and other myoblast specific 
markers[21,23,24]. Following proliferation, myoblast terminal differentiation is characterized by 
upregulation of Myogenin and Troponin T, a muscle-specific marker. During the course of 
muscle regeneration, a distinct  subpopulation of myoblast fails to differentiate, but remains 
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associated with the surface of the developing myofiber and reenters the quiescent state to 
replenish the satellite cell pool for subsequent muscle repair[14]. 
     In summary, SC are normally quiescent in mature skeletal muscles (e.g.,of the limbs). 
Quiescent SC are activated in response to diverse stimuli, including stretching, exercise, 
injury.  Activated SC  reenter the cell cycle and give rise to myoblasts, which undergo 
multiple rounds of proliferation prior to terminal differentiation and fusion with new or 
growing myofibers.       
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                                     (QUIESCENT)  SATELLITE CELL 
                                                            
                                                            PAX -7 +, Desmin- 
                                            c-met + ,CD34 +, and M-cadherin +                                 ? 
                                                                                                                                        
Phase A                           MUSCLE                       +FGFs/IGF-1/HGF/IL-6/ 
                                         DAMAGE                      +NOTCH           
  
                                     PROLIFERATING MYOBLAST 
                                                              Desmin + 
                                                      Myf-5 + / MyoD + 
                                                               
 Phase B                                                            Growth factor reduction 
                    
                                     DIFFERENTIATED MYOCYTE 
                                                       Desmin + /Myogenin + 
                                                       Myf-5  + / MyoD + 
                                                        
 
Phase C 
 
                                                     
                                                     Myofibers 
                                                      Troponin T + 
 
Figure 1 The activation, differentiation, and maintenance of satellite cells.  Following myofiber 
damage (phase A), quiescent satellite cells are activated to enter the cell cycle and proliferate, allowing 
for expansion of the myogenic cell population.  Proliferating myoblast are characterized by up-
regulating myogenic determination factors (MyoD and Myf-5) and the myoblast marker, desmin.  The 
proliferative phase is followed by terminal differentiation. Myoblast terminal differentiation (phase B)  
is characterized by the high expression of the Myogenin, muscle-specific marker as the Troponin T 
and fusion of myoblasts to damaged myofibers for repair or to each other for new myofiber formation 
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(phaseC).  During the course of muscle regeneration, a subset of myoblast reenters the quiescent state 
to replenish the satellite cell pool for subsequent muscle repair.  
 
3. Myoblast transplantation  
     MT is a potential cell-based technical therapy that aims mainly to treat DMD. According 
to the opinion of Skuk and colleagues[25], any treatment for a progressive myopathy should 
reach at least one of two degrees of therapeutic benefits which, in a sequence of increasing 
clinical improvement, are:(1) To slow down or stop the process of muscle degeneration. (2) 
To increase the force in wasted muscles.  
     Thus, the treatment to DMD must be either the introduction of the normal gene to 
substitute the affected one, or the correction of the defective gene, so as to increase the 
myogenic capacity of skeletal muscles. MT seems to meet the requirements for treating DMD. 
Skeletal muscle satellite cells display a capacity for self-renewal throughout the lifetime of an 
organism and has the potential to give rise to a large number of differenciated progenies. 
Satellite cells can be enzymatically isolated from skeletal muscle biopsy and proliferate in 
vitro, maintaining their capacity to fuse into myotubes that will differentiate into 
myofibres[13,14,15]. 
     Indeed, some previous research already demonstrated that MT is a potential method to 
treat DMD. It was reported[26] that the number of dystrophin-positive myofibers were 
preserved 8 months after myoblast transplantation, while the number of dystrophin-negative 
myofibers decreased, a phenomenon that was explained by the protective role of the donor-
dystrophin. Watt[27] et al tested the intramuscular injection of myoblast from neonatal mice as 
a method to introduce normal genes in myopathic muscles, demonstrating that they fused and 
formed hybrid fibers in regenerating mouse muscles. Morgan[28]  et al observed that myoblasts 
injected into completely cryodamaged muscles could repopulate almost 70% of these 
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muscles. Based on animal experiments, some groups conducted clinical trials and observed 
dystrophin-positive fibers in the transplanted muscles of a few DMD patients[29,30]. 
     MT is also emerging as a new strategy to heart failure. Yoon et al reported[31] that cultured 
myoblast to be implanted in dog hearts can give rise to new myocardium. Murry[32]et al 
demonstrated that skeletal myoblast could establish new muscle tissue, when myoblasts were 
grafted into injured  heart. Another study published that the cardiac function after myocardial 
infarction was improved after MT in vivo[33].  Ghostine [34] et al observed direct evidence that 
MT within infarcted myocardium increased global and regional contractile function, 
respectively.  Accordingly, these experiments suggest that MT is a possible method to treat 
cardiac failure. 
 
4. Hurdles to achieve  successful MT 
      A major problem, which hinders the efficacy of MT, remains the extremely high rate of 
early donor cell death, ie, during the first hours to days after transplantation, before the 
triggering of the specific immune response[1]. Many studies[14,35,36] have reported a massive 
and a rapid donor myoblast death ( ³90%) within the first hours after injection. Others[2,37], 
have described no significant loss of the transplanted cells during this period. To better 
understand cell survival after MT, the analysis is divided into two periods: an early survival 
(during the immediate hours or days after transplantation, before the acute rejection) and a 
long-term survival (defining long-term as the period needed for a clinical benefit, which 
ideally must be lifelong) [1]. The early survival of donor myoblasts is not well understood and 
some aspects remain controversial, principally link to the discordances that exist in the 
interpretation of results among different studies. These discrepancies can be explained by two 
factors, the difference in donor myoblast detection methods, and the difference in the  
reference standards used to assess 100% donor myoblast survival [1,2,25].  
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      Several factors are likely to be involved in cell death, including physical strain during 
injections, non-specific inflammation, apoptosis[7,38], necrosis[14,35,.36], and exposure to cell  
culture conditions[8].  Physical strain during injections could be handled by improving 
delivery devices and techniques, such as using the micro-syringe and aspiring slowly and 
gently the suspension of cells. Nonspecific inflammatory response is triggered by the needle 
punctures. Qu et al reported that myoblast engineered to express anti-inflammatory 
interleukin-1 showed better survival post-transplantation[36]. Whole body prior irradiation 
improved myoblast survival, and indicated that host immune cells are indeed contributing 
directly or indirectly to myoblast death[2,8,39]. The rapid death of injected myoblasts was 
observed following  transplantation in tacrolimus ( FK506 )-immunosuppressed mice[8]. This 
rules out a mechanism involving a specific immune reaction after transplantation.  
      The poor cell survival and early death of myoblasts have also been related to tissue culture 
conditions. The difference in the survival of skeletal myoblasts that are cultured and injected 
versus those that are directly implanted suggests that some aspects in the tissue culture 
conditions adversely affect the cells, thus rendering them incompatible with the host[40]. 
Similarly, enzymatic dissociation of skeletal myoblasts from donor tissue and subsequent 
trypsinization from tissue culture flasks during in vitro tissue culture, have deleterious effects 
on cells survival. Then in vivo, destruction of the donor myoblasts and myotubes may due to 
by-stander effects resulting from cytokines release such as TNF with cytotoxic action on all 
cells[41].  
     In the setting of interventions targeted at reducing cell death, pretreatment of cells(during 
the late stages of the culture process), either skeletal myoblast[9,38] or cardiomyocytes[7]with 
heat shock prior to implantation has also been shown to improve survival of intra-muscular or 
intra-myocardial grafts. The ability of HS treatment to reduce the number of TUNEL-positive 
transplanted cardiomyocytes suggests that one of its protective mechanisms could involve 
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limitation of apoptosis[7]. It is well known that mild HS treatment in various cells could 
induce heat shock proteins ( HSP ) expression and protect cells in vivo[7,9,38]. 
 
 
5. Heat Shock Proteins and Cell Protection 
 
5.1 Heat Shock Protein family 
       HSP were originally identified as proteins, whose expression was markedly increased by 
HS, and mediated by heat shock transcription factors (HSFs).  HSPs are expressed in in all 
type of cells  and play important functions in normal cell physiology. 
     HSPs, also called stress proteins, are highly conserved intracellular proteins which are 
present in all the different subcellular compartments (e.g. nucleus, mitochondria, chloroplast, 
endoplasmic reticulum, cytosol) of all cell types from prokaryotes and eukaryotes[10,42,43,44]. In 
addition to HS, a wide range of stimuli, such as physiological stimuli (growth factors, 
hormonal stimulation, hypoxia, ischemia, calcium increase, glucose deprivation, nitric oxide 
action, intense exercise), environmental stimuli (heavy metals, ultraviolet radiation), 
pathological stimuli (inflammation, autoimmune reactions, malignancies and viral, 
bacteriological, or parasitic infections), and cytotoxic drugs, were found to highly up-regulate 
HSP expression, known as the stress response[10,42,43,44].  
      HSPs are traditionally classified by their related function and respective molecular weight. 
In mammalian cells, stress response involves the induction of six major HSPs family, namely, 
small HSPs (exemplified by HSP27), HSP40, HSP60, HSP70, HSP90 and HSP100 ( Table 1 
)[10,42,43,44,45].  
 19 
5.2 Biochemical Activities of HSPs 
       HSPs protect a vast number of cell types against  diverses  insults, including protection of 
retina against light-induced injury[46], protection of the brain against ischemia/reperfusion[47], 
protection of the heart against ischemia/reperfusion[48,49,50,51], and protection of the 
hippocampal neurons against focal ischemia[52].  HSPs are also present  in blood of normal 
individuals, and their circulating levels are decreased in aging[53],  and increased in a number 
 
 
Table1 summary of the members and location of the major heat shock protein               
(HSPs)  families in mammalian cells 
 
 
 
 
                                                   Families                                         members                                   Location  
                                   Small heat shock proteins               αB-crystallin                              cytoplasm                                                                                                                                                                                             
.                                                                                             HSP27                                       cytoplasm/nucleus 
                                                                                              HSP32                                       cytoplasm     
                     
                                       HSP40                                           HSP40                                      cytoplasm/nucleus 
.                                                                                             HSP47                                      endoplasmic reticulum 
                                       HSP60                                           HSP60                                        mitochondrial 
                                       HSP70                                           inducible HSP70                         cytoplasm/nucleus            . .                                                                            
.                                                                                            constitutive HSP73(HSC70)        cytoplasm/nucleus                                                        
.                                                                                            Grp78/Bip                                    endoplasmic reticulum 
                                                                                             mito-HSP70(mHSP70)                mitochondrial 
                                       HSP90                                           HSP90                                         cytoplasm/nucleus      .                   
.                                                                                             Grp94                                          endoplasmic reticulum 
                                      HSP110                                          HSP105                                       cytoplasm  
 
 
of pathological conditions such as hypertension[54], atherosclerosis[55], and after open heart 
surgery[56]. 
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     As proteins, HSPs possess three principal biochemical activities. The first one is a 
chaperone activity[42,43,44,45], which prevents misaggregation of denatured proteins and assists 
in the refolding of denaturated proteins back into their native conformations[10,42,43,44,45] 
(Figure 2). Even in unstressed cells, some of the chaperone HSPs play a role in the folding of 
nascent polypeptides into native conformations during protein synthesis. Moreover, their 
ability to stabilize proteins in specific conformations is used by a variety of normal cellular 
regulatory processes, such as cell cycle control, antigen presentation by cells with immune 
function, and processing of steroid and vitamin D receptors. Prototypical HSPs with 
chaperone activity are HSP70, HSP90, HSP60.  
       The second essential activity of HSPs is the regulation of the cellular redox state, which is 
best illustrated by HSP32, also known as heme oxygenase-1[10]. 
     The third principal biochemical role of HSPs is the regulation of protein turnover[42,43,44,45]. 
For example, Ubiquitin, one of the smallest HSPs , is expressed in unstressed cells and is up-
regulated by heat shock, and also serves as a molecular tag to mark proteins for the 
degradation by proteasomes.    
       Protective effect of HSPs in myoblast [9,37] occurs in a variety of other tissues and cell 
types , such as heart and brain[43,44].  Mechanism is not yet clear, but it may result from the 
prevention of protein denaturation by the intrinsic chaperone activity of HSPs. 
      Increased expression of HSP has been described in association with a variety of diseases, 
including ischemia and reperfusion damage, fever and inflammation, metabolic disorders, cell 
and tissue trauma, aging, infection, and cancer[43,44,49,50,51,52,53,54,55,56]. The cytoprotective role 
of HSPs is particulary prominent in the anti-apoptosis field.  Apoptosis, which is an important 
mechanism of cell death after transplantation[7,38],  is an adaptive mechanism that control cell  
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Figure 2   Protective effect of HSPs  
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death without sacrificing the organism’s survival. At the same time, the stressed cells induce 
HSP overexpression  as key determinants in the regulation of apoptosis[57].  
     HSPs, including HSP70, HSP27 and HS P90, interfere with extrinsic (receptor-mediated) 
and intrinsic (mitochondria-mediated) signalling pathways that lead to proteolytic activation 
of caspases[57], the major effectors of apoptosis, with the capacity of specifically cleave 
proteins at aspartate residues. The intrinsic signalling pathway involves BH3-only members 
of the Bcl-2 family (including Bid, Bim, Bad, and others), which may function as context-
specific sensors for cell damage and converge on the mitochondria to trigger their 
permeabilization. Whereas the extrinsic pathway is initiated by the plasma membrane proteins 
of the tumor necrosis factor (TNF) receptor family, known as death receptors.  
 
5.3 HSP70 and Cell Protection 
     HSPs are expressed constitutively and inducibly in different cellular compartments. 
Members of the HSP70 family exhibit complex patterns of growth-regulated and stress-
induced gene expression and are targeted to different subcellular compartments. Heat shock 
constitutive 70 (HSC70) and the stress-induced HSP70 (HSP72) proteins are cytosolic and 
nuclear, whereas the glucose-regulated protein 78 (Grp78/BIP) is localized at the endoplasmic 
reticulum and mitochondrial HSP70 (mHSP70, or mito-HSP70) is a mitochondrial-localized 
protein[42,43,44,45].  
     HSP70, the most extensively studied HSP, is a self-preservation protein whose role is  to 
maintain cellular homeostasis under stress. Under normal conditions, HSP70 function as an 
ATP-dependent molecular chaperones, playing an essential role in mediating the folding of 
newly synthesized polypeptides, the assembly of multiprotein complexes, the transport of 
proteins across cellular membranes, and the degradation of unstable proteins[42,43,44,58,59]. 
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Under stressful conditions, synthesis of inducible HSP70 enhances the ability of cells to cope 
with increased concentrations of unfolded or denatured proteins, i.e, helping to prevent 
protein denaturation and aggregation, assisting in refolding or removal of damaged proteins, 
and inhibiting apoptosis[42,43,44,59,60]. 
     It has been reported that  HS treatment up-regulates HSP expression (including HSP70), 
which are associated with cell  protection in vivo and in vitro situations[42,43,44]. It was 
proposed that the increased synthesis of HSP may reflect the requirement for these proteins to 
protect different protein structure within the diverse cellular compartments. The 
cytoprotective role of HSP, and in particular of HSP70, has been extensively documented in 
vitro as well as in vivo in a varitey of human diseases, including metabolic disorders, 
inflammation, infection, and ischemia[42,43,44,61,62,63].  Therefore in the present study, we  chose 
HSP70 as it is one of the major standards for evaluating the effect of HS treatment on 
myoblasts.   
     HSP70 inhibits Caspase-dependent apoptosis by several mechanisms upstream and 
downstream of caspase inactivation. Caspase-dependent apoptosis, the classical and major 
pathway of apoptosis, involves the release of cytochrome C from mitochondria. In turn, 
cytochrome C binds to apoptotic protease activation factor-1 (Apaf-1), which is a component 
of the apoptosome, and triggers the ATP-dependent oligomerization of Apaf-1[64,65]. This 
complex then attracts the inactive, unprocessed pro-form of the proteolytic enzyme caspase-9 
which is then cleaved to its active form, thereby triggering the proteolytic maturation of pro-
caspase-3 and initiating the apoptotic process[57,66,67,68,69] (Figure 3).  
       Two studies[59.60] reported that HSP70 inhibit apoptosis by binding directly to Apaf-1, and 
preventing oligomeris Apaf-1 from recruiting pro-caspase. In addition, HSP70 might be 
involved in preventing a proposed caspase-independent apoptosis by suppressing c-Jun N-
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terminal kinase (jnk kinase), which plays a key role in inducing apoptotic cell death in 
response to specific stimuli[66.67]. In addition to HSP70, HSP90 and HSP27 can also inhibit  
Figure 3     HSPs in the regulation of the major events in apoptosis. 
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apoptosis. HSP90 alone or together with HSP70 binds Apaf-1 and inhibits it binding to 
cytochrome C, thereby preventing the activation of caspase-9[68].  HSP27 has been shown to 
bind to cytochrome C and inhibits it’s binding to Apaf-1[69,70]. On the other hand, HSP60 
alone or in combination with HSP10 can directly stimulate apoptosis by promoting the 
proteolytic maturation of caspase-3[71,72]. 
        HSP70 can enhance nitric oxide (NO) production in response to cytokine stimulation[73]. 
NO can protect cultured cells from TNF-a-induced cell death by inducing HSP70.      
      In addition to the inhibition of apoptosis, which is the most important mechanism of 
HSP70 cytoprotection, HSP70 also appear to have other protective effects.  Over-expression 
of HSP90 can also bind to endothelial nitric oxide synthase (eNOS) and stimulate its 
activity[74] . Over-expression of HSP27 can protect the integrity of the microtubules and the 
actin cytoskeleton in cardiac myocytes and endothelial cells exposed to ischaemia[75,76].  
     In addition to these properties described above, HSP70, which is the main highly inducible 
HSP, can also influence a variety of immunological processes. HSP70 could chaperone 
antigenic peptides and deliver these into antigen-presentation pathway within antigen- 
presenting cells (APC)[77,78]; activate and regulate innate and adaptive immunity[79,80,81,82].  
 
6.The Aims of Our study  
    The aims of the present study are: (1) to determine whether mild HS pre-treatment at 42ºC 
can induce overexpression of HSP 70 in intact porcine myoblasts; (2) to determine whether 
HS treatment change the myogenic characteristics of porcine myoblasts; and (3) to determine 
whether HSP70 over-expression improves myoblast survival after autologous transplantation 
in vivo. 
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                                                     MATERIAL AND METHODS  
 
Animals 
        
        All experimental and animal care procedures in this study were conducted in accordance 
with the national as well as international guidelines.  Seven domestic female pigs (Animalerie 
d'Arare, Université de Genève, Plan les Ouates, Switzerland) were used (body weight of  
20.3 ± 2.5 kg  and age of 2 months ± 1 week) in the present study.  
Materials 
Buffer, medium and serum 
         The following buffers and media were used: Hank’s Balanced Salt Solution without cal-
cium and magnesium (HBSS) based collecting buffer [pH 7.4, 10% HBSS(Invitrogen), 2.38 
mg/ml Hepes, 5 µg/ml Gentamycin (Invitrogen, Basel, Switzerland)]; Solution A [pH 7.15, 
1.98 mg/ml Glucose, 7.6 mg/ml NaCl, 0.02 mg/ml KCl, 0.18 mg/ml Na2HPO4H2O, 7.15 mg / 
ml Hepes, 0.2% Phenol Red (Invitrogen) ]; Wash medium [80% F10 Nutrient mixture ( Invi-
trogen ), 20% FCS (Readysystem, Kibbuth Beth Halmek, Israel) and 5 µg/ml Gentamy-cin ]; 
lyses buffer [pH 7.5, 10% Tris-HCl (26.6 mg/ml), 90% NH4Cl (6.82 mg/ml)];   TNE solution ( 
50mM  Tris HCL pH7.4,150mM Nacl, 1mMEDTA); in Tris-buffered saline-Tween20 (TTBS, 
20mM Tris-HCL (pH7.5), 137mM Nacl and 0.1%Tween 20); PBS(pH7.3,137mM Nacl, 2.47 
mM KCL, 4.3mM Na2PO4-7H2O, 1.4mMKH2PO4,GM [Growth medium, 80% a-MEM  (Inv-
itrogen), 20% MCDB 110 (Sigma, St-Louis, MO,  USA) containing 0.5 mg / ml BSA, 100  ml 
/ml Transferin , 0.18 mg/ml Insulin , 15 mg/ml Creatinin, 5 µg/ml Gentamy-cin, 3.9 mg/ml 
Dexamethason (Sigma), 10 mg/ml b- FGF (Invitrogen), 100 mg/ml EGF ( Bec-ton Dickinson, 
Allschwil, Switzerland)]; DM [differentiation medium, 50% 4/1 aMEM, 50% BSA and 5 µg 
/ml Gentamycin].  
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Myogenic precursor cell isolation and culture 
 
    Pig MPC were isolated following a modified method that was  previously described for the 
isolation of human myoblasts[83]. A pig skeletal muscle biopsy was taken from the vastus 
medialis muscle. The biopsy was minced and enzymatically dissociated with Protease (Sigma, 
0.14 mg/g of muscle) for 90 min (rather than 60 min) at 370C while stirring. The enzymatic 
dissociation was stopped using 10% of either FCS. The preparation was filtered through a 
40 mm nylon cell strainer (Becton Dickinson). After centrifugation (at 350g for 5 min), cells 
were washed to eliminate extra-cellular matrix and the erythrocytes were lysed. After 
washing, the number of living cells was counted using Trypan blue exclusion test.  Cells were 
reseeded at approximately 5´105 cells per 75cm2 flasks(for in vitro or vivo experiment, Iwaki 
glass, Tokyo, Japan) and 2.5´104 cells per 35mm dish (for in fusion index experiment, Iwaki 
glass, Tokyo, Japan ). 
      Both flask and dish were pre-coated with gelatin. The cells were expanded at 37°C in a 
humidified atmosphere with  7% CO2 in GM containing 15% of FCS and used at passage 1 
for all transplantation experiments.  After 8 days in GM,  myoblasts  were further cultured in 
DM for another 3 days and then used  for  in vitro studies of  myogenic properties (fusion 
index). 
 
Heat shock treatment 
       Subconfluent cultured cells in 35-mm dishes or 75-cm2 flasks (for in vitro or in vivo 
experiment) were exposed to hyperthermia at 420C with 0.5% CO2 for 60 min (HS treatment) 
in a oven.  Fresh GM was always added before heating the cells.  Immediately after heat 
stress, the culture medium was replaced with fresh GM (DM, in fusion index experiment). 
The heat shock cells (HS cells) were then incubated for 24 hours at 370C, 7% CO2).  As a 
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control, non-heat shock treated cells (non-HS cells) were kept under normal conditions 
without hyperthermia (370C, 5% CO2).    
 
 
In vitro experiments 
     HSP70 expression and fusion index of the cells was evaluated in vitro with or without 
prior heat shock treatment. 
Western Blots 
          Confluent monolayer of cells were washed with cold PBS then scraping within a  TNE 
solution and homogenated. The homogenate was diluted in Lammeli's sample buffer (1׃ 1) 
with 5 % β-mercaptoethanol ( Bio-Rad laboratories, USA). The mixture was boiled at 100˚C  
for 5 min, cooled on ice and then stored at -20˚C until used .  The Bradford method (Bio-RAD 
Protein Assay), with bovine serum albumin (BSA) as the standard, was used to determine the 
protein concentration in samples.   
        Protein (15mg) was loaded onto an  sodium dodecyl sulfate (SDS) 8% polyacrylamide 
gel After 1-dimensional electrophoresis, the proteins were transferred onto a western 
polyvinylidene difluoride (PVDF) membrane ( Bio-Rad laboratories, Germany) by electro-
elution.  Western blots were incubated 1 hour in TTBS-5% nonfat milk to block nonspecific 
binding sites. After  blocking, blots were incubated 1 hour with the primary antibodies diluted 
in TTBS-5% nonfat milk as follows: mouse antibody against human HSP70 ( Merck),1׃1000;  
mouse antibody against  human Desmin (clone D33, DAKO A/S, Den-mark) mouse 
monoclonal antibody against α-Tubulin(clone DM1A, Sigma), 1 ׃ 5000. After washing,   
western blots were incubated 1 hour with a horseradish peroxidase conjugated goat anti-
mouse antibody diluted 1׃3000.   
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      Blots were visualized using an enchanced chemiluminescence (ECL) detection system 
(Amersham Biosciences). A semi-quantitative measurement of the normalized relative 
intensity of each protein band was evaluated using  OptiQuant  software (Version 03.2000, 
Packard instrument Co.). 
 
Flow cytometry 
       
     Confluent monolayers of HS or non-HS cells were harvested using routine trypsin-EDTA 
detachment, resuspended in PBS (100'000 cells per condition) and washed twice in either PBS 
-1%FCS (CD56) or PBS (Desmin and HSP70). As no pig-specific antibodies were available, 
commercial anti-human reagents of the required specificity were tested for cross reactivity 
with the respective pig antigens. CD56 staining: cells were incubated on ice for 60 min with a 
mouse anti-human CD56 antibody (Ab) conjugated to fluorescein iso-thiocyanate (FITC) 
(clone NCAM 16.2, Beckton Dickinson) in the presence of mouse total Immunoglobulin  
(Sigma).  Negative control was done by incubating the cells with an isotype mouse IgG2a 
FITC antibody (Becton Dickinson), using the same protocol. Desmin/HSP70 staining: Cells 
were permeabilized by incubation on ice for 20 minutes with a Fix/Perm buffer (Becton 
Dickinson).  Then Cells were washed twice in Perm/Wash buffer 1x (Becton Dickinson) and 
unspecific sites blocked using a 15 min incubation with a buffer containing 50% of human 
male type AB serum (Sigma) and 50% of a Perm/Wash buffer 2X. Cells were then incubated 
with a mouse anti- human desmin Ab for 90 min on ice (clone DE-R11, Dako, Glostrup, 
Denmark) or a mouse monoclonal anti-human HSP70 Ab (Merck), washed twice and 
incubated 20 min on ice with goat anti-mouse IgG FITC (Sigma). Negative control was done 
using a purified mouse IgG1 isotype as the 1st Ab (clone MOPC-21, Beckton Dickinson). The 
samples were then resuspended in PBS and the fluorescence measured using a 
FACSCalibur(Becton Dickinson).  Data were analyzed using the CellQuest software (Becton 
Dickinson).  
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Fusion  index 
     Conflent monolayer of HS treated and non-HS cells were cultured in DM for 3 days at  
370C, 5%CO2. 
     Cells were fixed in PBS 4% formaldehyde for 10 min, washed with PBS and permeabilized 
by 20 min incubation in PBS-0.25% Triton. After washing, unspecific sites were blocked by 
15 min incubation in PBS-0.1% Tween 20-2% goat serum (Sigma). Cells were  incubated for 
90 min with a mouse anti human Troponin T Ab (clone JLT 11, Sigma) and washed twice. 
After incubation for 60 min with a goat anti mouse FITC (Sigma), all nuclei were stained 
using a  fluorescence specific, DAPI containing, (Vector Labora-tories, Burlingame, CA, 
USA), mounting medium. For each sample,  27 randomly chosen fields (objectives X 20) had 
their green (troponin T in myotubes) and blue (nuclei) labeled surfaces outlined by an 
investigator and the fusion index (defined as the number of DAPI stained nuclei inside 
myotubes divided by the total number of DAPI stained nuclei in the entire field of interest) 
was automatically calculated with the software Metamoph (Zeiss, Felbach, Switzerland). 
Labelling of porcine MPC before transplantation for histological analysis 
      The non-HS cells were transfected using a lentiviral vector coding for a nls-lacZ reporter 
gene. The nls-lacZ gene is expressed under the control of the constitutive active promoter 
from human elongation factor Ia. For histological analysis, nls-lacZ marked non-HS cells 
were transplanted in the tibialis anterior muscle. Four close injections of 40 ml containing 
18x106 cells in total were performed as described below. After 8 days, a biopsy was taken, 
fixed in 2% formaldehyde in PBS for 24 hours while stirring, before being stained for b-
galactosidase. 
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Histological analysis and b-galactosidase staining 
 
Biopsies were stained with a solution containing 5 mM K3Fc(CN)6 , 5 mM K4Fc(CN)6, 
2mM MgCl2, 0.02 g/ml NaDC, 0.02% NP-40 (Fluka), 1 mg/ml X-gal (5-Bromo-4-chloro-
indolyl-b-D-galactopyranoside  in PBS (-)1X for 48 hours at 37oC while stirring. After 24 
hours, the staining solution was changed. These biopsies were fixed in 5% formaldehyde in 
PBS (-) 1x for 24 hours at 4oC, imbedded in paraffin, and routinely processed for 
Haematoxylin-Eosin staining on gelatine coated slides. 
 
 
In vivo experiments 
 
       To quantify cell mortality, which occurs after transplantation, myoblasts were radio 
labeled by culturing them for 16 hours in GM containing containing 5 mCi/ml of 3[H]-
thymidin (Hartmann Analytic, Braunschweig, Switzerland). 
 
 
MPC transplantation  
 
        Isoflurane (Abbott, Baar, Switzerland) was used as the anesthetic in all procedures, 
supplemented with oxygen through a semi-closed circuit inhalation system. Pigs were 
anaesthetized, the skin overlaying skeletal muscle was opened and 40 ml of the cell 
suspension (1.6 x 106 cells) was injected in the muscle using a 50 ml syringe with a 27-gauge 
needle (Hamilton Company, Bonaduz, Switzerland). The sites of injection were identified by 
placing four non-absorbable sutures in the surface of the muscle, and the suspension of cells 
was injected centrally.  Biopsies were taken at 0, 24, 48 and 120 hours after injection. After 
surgery, pigs received daily intramuscular injection of cefuroxim 750 mg (Zinacef, 
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GlaxoSmithKline, Münchenbuchsee, Switzerland) for three days and fentanyl 1 µg/10 kg 
(Sintenyl, Sintetica S.A., Mendrisio) for two days.   
 
Measurement of  Myoblast Survival 
        Before injection, 3 biopsies were taken from the same pig muscle for blank 
measurements. To determine the reference 100% survival, 40ml of the cell suspension was 
injected ex vivo into native muscle samples immediately after a biopsy (ex vivo T0). Biopsies 
were stored at –20°C until use. All biopsies (about1´1´2cm3) were homogenized in a 
Beckman Tissue Solubilizer-450 (BTS-450, Beckman Coulter, Krefeld, Germany) solution 
until it completely dissolved at 37°C while stirring.  The amount of radio label within each 
biopsy was measured with a Beckman LS 600 TA counter system (Beckman Coulter) by 
mixing 500 ml of dissociated muscle with 10 ml of liquid scintillation cocktail (Ready 
Organic, Beckman Coulter).  
 
Statistical analysis 
     Stastical comparison was performed by Student’s T test. A value of P < 0.05 was 
considered as significant. 
 
 
Results 
 
Heat shock pretreatment upregulate HSP70 expression in pig MPC 
    HSP70 level was evaluated in HS or non-HS cells by western blotting. Figure 5A shows a 
significant over-expression of HSP70 within the HS cells. Desmin and  α-Tubulin expression 
was constant in all lanes, indicating equal protein loading on the blot. 
 
     According to semiquantitative analysis with computed densitometry, HSP70 expression in 
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HS cells represented  more than two-fold increase as compared to non-HS cells (0.659 ± 
0.016 and 0.292 ± 0.015 % respectively, P < 0.01) (Figure 5B). In contrast, There was no 
significant difference in Desmin expression between HS cells and non-HS cells (0.398 ± 
0.009 and 0.404 ± 0.005 % respectively, P > 0.05) 
                                                                                                      42oC,  1 hour         
                                                                      
                       
                         non-HS 1    non-HS 2    non-HS 3      HS-1            HS-2            HS-3 
 
Hsp70              
Desmin      
a-Tubulin         
 
Figure 5A:  MPC were incubated or not at 42oC during 1 hour and the proteins were 
harvested 24 hours after treatment.  A 2-fold over-expression of HSP70 was observed within 
the HS treated cells as compare to non-HS cells. Whereas Desmin expression was stable after 
the treatment.  α –Tubulin indicated that  the same quantities of protein had been loaded on 
each well.    
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Figure 5B: Quantification of HSP70 expression by densitometer analyses.  Heat Shock 
treatment increased by 2 times the level of HSP70 expression ( P < 0.01 ) .  
 
      To confirm these data, 24 hours after heat shock, HS or non-HS treated cells were 
analysed by flow cytometry for HSP70 expression. HSP70 expression in HS cells was more 
than 4-fold higher than non-HS cells (30.61 ± 1.31 and 7.35 ± 0.76, the median fluorescence 
for HSP70,  P = 0.004 ) (Figure 6).  
       
Heat Shock treatment does not change myogenic properties of MPC 
      Pig myoblasts were  phenotyped by flow cytometry with markers for CD56 and Desmin.  
Consistent with the result obtained by western blotting,  HS or non-HS cells showed similar 
level of desmin and CD56.  We also measured the fusion index of HS or non-HS cells in order 
to confirm their myogenic properties. The dissociated  myogenic  pig cells proliferated well in 
growth medium (Figure 7A) and  could be induced to fuse, yielding myotubes in 
differentiation medium with or without prior heat shock treatment (Figure 7B).   The myotube 
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were labeled with troponin-T, a muscle  specific protein expressed by mature myotubes ( 
Figure 7C).  
        The fusion index of HS  and non-HS treated cells (n=3 petri dishes/group), measured 
with a semi-automated bioimaging technique, were respectively 63.69 ± 1.22 %, 64.78 ± 1.26 
%. .  There was no signigicant difference in the fusion index of the two groups ( P = 0.49 ). 
Thus, after heat shock treatment, cells kept their myogenic properties as non treated cells. 
 
 
Donor cells fuse with host myotubes 
   Lentivirus are known to transduce purified human myoblasts and porcine muscle 
cells efficiently in vitro, without loss of myoblast proliferation and differentiation caused by 
toxicity[84]. Cells treated or non treated transduced with the nls-lacZ lentiviral construct kept 
their capacity to differentiate and to fuse, forming myotubes expressing the marker gene after 
8 days in culture, followed by 72 hours  in DM . 
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Figure 6:  HSP70 over-expression after  heat shock treatment. 24 hours after treatment, HS 
and non-HS MPC were analyzed by FACS for HSP70.  HS treatment  significantly increased 
by 4 times HSP70 expression as compared to non-HS cells ( 30.61 ± 1.31 and 7.35 ± 0.76, 
respectively, P = 0.004 ).  Average values at six experiments are illustrated with indication of 
the standard deviation. 
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           Figure A               
 
            Figure B              
 
              Figure C            
 
Figure 7   Freshly isolated MPC keep their myogenic capacity to proliferate and fuse.  (A) Fresh 
isolated MPC grown in GM. x 10 objective, scale bar: 200 µm.  (B) MPC grown to confluence 
between 6 to 8 days in growth medium and then transferred in differentiation medium for another 3 
days. Aligned nuclei are typical of myotubes. x 10 objective, scale bar: 200 µm.  (C) In another 
culture, myotubes are stained with an Ab against troponin-T (green) and nuclei are stained with DAPI 
(blue). Nuclei of non-fusing cells are clearly seen between myotubes.  x 40 objective, scale bar: 50 
µm. 
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Histological analysis  
    We injected nls-LacZ transduced non treated cells in vivo and biopsies were taken at 8 days 
post-transplantation for histological analysis. Histological assessment showed that X-gal 
positive nuclei confirmed the presence of hybrid regenerating myotubes containing both 
transplanted (non HS treated cells) and host  nuclei ( Figure 8). 
MPC survival significantly improved in vivo 
     
    HS or non-HS treated MPC were incubated with 3[H]-thymidine for 16 hours before 
transplantation.  MPC were transplanted at various sites into the same pig skeletal muscle. 
Muscle biopsies were harvested at various time, from 0 to 120 hours after transplantation. 
Graft cell survival rate was evaluated by measuring the radioactivity within the biopsy (n=7).  
Twenty-four hours after injection, cell-survival (with respect to T0) in HS and non-HS  was 
67.7 ± 8.35 % versus  52.9  ± 10.82 %, respectively. There was no significant difference 
between these two condition ( P>0.2 ). However, the mean cell-survival at  48 hours after 
transplantation in HS and non-HS treated cells was 52.3 ± 8.22 % and 22.0 ± 5.90 %, 
respectively.   Likewise, the mean levels of cell-survival rate at 120 hours after transplantation 
in HS and non-HS treated cells was 26.3 ± 5.54 % and 8.7 ± 3.34 %, respectively. The 
difference in survival  of grafted cells at 48 hours ( P< 0.05 ), and at 120 hours after graft  ( P 
< 0.01) were statistically significant (Figure 9). 
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Figure 8  Histology of pig muscles 8 days after transplantation of nls-LacZ transduced non-
HS MPC. Porcine muscle biopsies were stained with eosin ( red cytoplasm) after X-gal 
staining (blue nuclei). This confirmed the presence of donor cell nuclei in host myotubes. The 
shown sections are representative of five analyzed grafts. objective x20, scale bar: 50 µm. 
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Figure 9  Survival of porcine myogenic precursor cells (MPC) transplanted into intact 
skeletal muscle. HS or non-HS  were incubated with 3[H]-thymidine 16 hours before 
transplantation in pig skeletal muscle. A biopsy were performed at the beginning of the 
experiment at T0, and the radioactive counts were taken as 100%.  The remaining 3[H]-
thymidine was quantified as the ratio of (cpm at time T/mg of tissue)/(cpm at time T0/mg 
*
** 
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tissue), at 24, 48 and 120 h after transplantation. Dark bars represent the HS group, and clear  
bars represent non-HS group. There was no significant difference between the HS and non-
HS at 24 hours after the graft (67.7 ± 8.35% versus 52.9 ± 10.82 %, P>0.2).  The survival rate 
of grafted cells was improved at 48 hours after transplantation (52.3 ± 8.22 % versus 22.0 
± 5.90 %,*P = 0.014). Compared with non-HS conditions, the survival rate of HS cells 
increased more than 3 fold at 120 hours after graft  (26.3 ± 5.54 % versus 8.7 ± 3.34 %,** P < 
0.01). 
 
 
 
 
Discussion 
 
     HSPs, also called stress proteins, are a group of proteins present in all cells. These proteins 
have been shown to protect cells against subsequent insults, including a cross-tolerance to 
stimuli of a different type than the original; ie, a cell exposed to hyperthermia will acquire 
resistance to damage from other harmful stimuli[38,42,43,44], applied subsequently. Previous 
studies have revealed an association between the  HS treatment and enhancement of cells 
survival after transplantation in heart[7,9].  Bouchentouf et al [38]  reported that  HS treatment 
can improve myoblast survival after transplantation in MDX mice. In the present study, we 
demonstrate that HS treatment of porcine myoblast is associated with significant HSP70 over-
expression that improve cell survival after autologous transplantation in intact pig skeletal 
muscle. 
       Among the HSP family members, HSP70 is the most abundant proteins following heat 
shock treatment[43].  The cytoprotective function of HSP70 has been extensively documented 
in inflammation, infection and ischemia[42,43,44,61,62,63].  Therefore, in our study, we choose 
HSP70 as one of the major standards for evaluating the effect of heat shock treatment on 
porcine MPC. 
       In our in vitro experiments, the level of HSP70 in western blots has been shown to be 
twofold higher in HS treated cells than in non treated cells. In FACS, however, there was 
more than a fourfold increase in the expression of HSP70 in HS treated cells than that in non 
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treated cells. We attribute this difference to the methods used. We proposed that  HS 
treatment may increase the proportion of  HSP70-positive cells as showed by FACS, which 
express  different levels of HSP70. 
       To evaluate whether the myogenic characteristics of myoblast is altered by HS treatment 
or not, we checked the expression of desmin, CD56, and the rate of  fusion index. Our data 
showed no significant difference between HS treated cells and non treated cells. Accordingly, 
it can be concluded that the HS treatment did not change the myogenic properties of 
myoblasts. 
    Our data within in vivo experiment is in line with the study of Bouchentouf et al[38]. In 
MDX mice, after HS treatment, survival of HS treated cells was increased by twofold 5 days 
after transplantation[38]. In our investigation, survival of HS treated cells increased by 
threefold 5 days after transplantation, and was also enhanced by nearly twofold 48 hours after 
transplantation (P<0.01). We suggest that the difference observed at 48 hours may be due to 
species difference including subtle difference in  HSP70 expression. 
    Necrosis and apoptosis are two major pathways of the early cell death after transplantation. 
In the case of necrosis, the cell membrane looses its integrity and the cell content is released 
causing an inflammatory response. Differently, the apoptotic cell content remains in the 
apoptotic bodies and inflammation does not occur. Both necrosis and apoptosis can[85] be 1) 
caused by the same pathophysiological exposure ( e.g., cytokines, ischemia, heat, irradiation, 
pathogens); 2) can be prevented by antiapoptotic mechanisms; 3) can be transformed from 
one form to another. 
          It is reported that necrosis seems to be the first mechanism of donor cell death during 
the first 24 hours post-transplantation[86].  Indeed, the activation of caspase-3  was negligible 
at this time. Beauchamp[16] et al showed that there was no evidence of donor cell apoptosis 
during the first 6 hours after MT.  We did not test apoptosis in our model, but by analogy , we 
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suggest that  necrosis was the most important pathway of cell death during the first 24 hours 
post-transplantation. In this period, the death of grafted myoblast may be mainly due to the 
physical strain stress during injection and the resulting inflammation and necrosis.  
        HSP70 protect the cells via multiple mechanism, which include prevention of 
apoptosis[38,42,87,88], necrosis[42], and inflammation[38]. The inflammation, which is initiated by 
intramuscular MPC injection and is characterized by a prodution of tumor necrosis 
factor(TNF)- a in vivo[38], HSP70 can protect mammalian cells from TNF a- and b- mediated 
cytotoxicity[89] ( for detailed description on the cytoprotective function of HSP70, see 
introduction 5.3).  
      In our in vivo experiments, although the HS treatment already upregulated the expression 
of HSP70 in HS treated cells before transplantation, there is no significant difference in the 
survival of  HS treated cells and non treated cells, 24 hours after transplantation. Therefore, 
we suggested that HSP70 mediated  cytoprotection may not be effective during the first 24 
hours post-transplantation. However, the survival of grafted HS treated cells was significantly 
enhanced at 48 hours and 120 hours after transplantation (P<0.01). We speculate that the 
apoptosis may have been the major pathway of the cell death at times between 48 hours and  
120 hours after the transplantation, when the function of HSP70 anti-apoptosis, together with 
other cytoprotections of HSP70, began to play an obvious role.  
         In fact, HSP70 may not  be the only molecule, involved in the protection of grafted cells 
in vivo. Heat shock treatment is reported to induce other HSPs (e.g., HSP32, HSP90, HSP27) 
and other molecules including superoxide dismutase[90].  The specific role of HSP70 with 
respect to other molecules in myoblast  will be the object of further studies. 
       Although the mechanism by which the HS treated cells survived better  at 48 hours and 
120 hours after transplantation remain unclear, these experiments will help in the 
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development of strategies to achieve an efficient MT method for muscle disorders and severe 
muscle injury.  
 
 
 
 
 
Conclusion 
      We have demonstrated that HS pre-treatment increased the expression of  HSP70 in 
porcine myoblasts in vitro, and improved myoblast-survival rate after autologous 
transplantation in vivo.  Therefore, HS pre-treatment may be a simple and effective way to 
increase myoblast survival after transplantation in pig, and may represent a potential method 
to improve myoblast transfer in patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 43 
Reference 
 
1. Skuk D, Tremblay JP. Cell therapies for inherited myopathies. Curr Opin Rheumatol. 2003 Nov; 15 
(6) : 723-9.  
 
2. Sammels LM, Bosio E, Fragall CT, Grounds MD, van Rooijen N, Beilharz MW. Innate 
inflammatory cells are not responsible for early death of donor myoblasts after myoblast transfer 
therapy. Transplantation. 2004 Jun 27;77(12):1790-7. 
 
3. Thompson RB, Emani SM, Davis BH, van den Bos EJ, Morimoto Y, Craig D, Glower D, Taylor 
DA. Comparison of intracardiac cell transplantation: auto-logous skeletal myoblasts versus bone 
marrow cells. Circulation. 2003 Sep 9;108 Suppl 1:II264-71. 
 
4. Yoo KJ, Li RK, Weisel RD, Mickle DA, Jia ZQ, Kim EJ, Tomita S, Yau TM.Heart cell transplan-
tation improves heart function in dilated cardio-myopathic hamsters. Circulation. 2000 Nov 7;102(19 
Suppl 3):III204-9. 
 
5. Boubaker el Andalousi R, Daussin PA, Micallef JP, et al. Changes in mass and performance in 
rabbit muscles after muscle damage with or without transplantation of primary satellite cells. Cell 
Transplant 2002;11(2):169-80. 
 
6. Ozawa E, Noguchi S, Mizuno Y, Hagiwara Y, Yoshida M. From dystrophinopathy to 
sarcoglycanopathy: evolution of a concept of muscular dystrophy. Muscle Nerve. 1998 Apr;21(4):421-
38. 
 
7. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE. Cardiomyocyte grafting for cardiac 
repair: graft cell death and anti-death strategies. J Mol Cell Cardiol. 2001 May;33(5):907-21.  
 
8. Smythe GM, Hodgetts SI, Grounds MD. Immunobiology and the future of myoblast transfer 
therapy. Mol Ther. 2000 Apr;1(4):304-13. 
 
9. Suzuki K, Smolenski RT, Jayakumar J, Murtuza B, Brand NJ, Yacoub MH. Heat shock treatment 
enhances graft cell survival in skeletal myoblast transplantation to the heart. Circulation. 2000 Nov 
7;102(19 Suppl 3):III216-21. 
 
10. Otterbein LE, Choi AM.  Heme oxygenase: colors of defense against cellular stress. Am J Physiol 
Lung Cell Mol Physiol. 2000 Dec;279(6):L1029-37. 
 
11. Tamaki T, Akatsuka A, Ando K, Nakamura Y, Matsuzawa H, Hotta T, Roy RR, Edgerton VR . 
Identification of myogenic-endothelial progenitor cells in the interstitial spaces of skeletal muscle. J 
Cell Biol. 2002 May 13;157(4):571-7.  
 
12.  Asakura A, Seale P, Girgis-Gabardo A, Rudnicki MA. Myogenic specification of side population 
cells in skeletal muscle. J Cell Biol. 2002 Oct 14;159(1):123-34.  
 
13.  Zammit PS, Heslop L, Hudon V, Rosenblatt JD, Tajbakhsh S, Buckingham ME, Beauchamp JR, 
Partridge TA. Kinetics of myoblast proliferation show that resident satellite cells are competent to 
fully regenerate skeletal muscle fibers. Exp Cell Res. 2002 Nov 15;281(1):39-49.  
 
14.  Schultz E. Satellite cell proliferative compartments in growing skeletal muscles. Dev Biol. 1996 
Apr 10;175(1):84-94.  
 
 
 
 44 
15. Blanton JR Jr, Grant AL, McFarland DC, Robinson JP, Bidwell CA. Isolation of two populations 
of myoblasts from porcine skeletal muscle. Muscle Nerve. 1999 Jan;22(1):43-50.  
 
16. Beauchamp JR, Morgan JE, Pagel CN, Partridge TA. Dynamics of myoblast transplantation reveal 
a discrete minority of precursors with stem cell-like properties as the myogenic source. : J Cell Biol. 
1999 Mar 22;144(6):1113-22.  
 
17. Seale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, Gruss P, Rudnicki MA. Pax7 is required 
for the specification of myogenic satellite cells. Cell. 2000 Sep 15;102(6):777-86.  
 
18. Gibson MC, Schultz E. The distribution of satellite cells and their relationship to specific fiber 
types in soleus and extensor digitorum longus muscles. Anat Rec. 1982 Mar;202(3):329-37. 
 
19. Conboy IM, Rando TA. The regulation of Notch signaling controls satellite cell activation and cell 
fate determination in postnatal myogenesis. Dev Cell. 2002 Sep;3(3):397-409.  
 
20. Sheehan SM, Allen RE. Skeletal muscle satellite cell proliferation in response to members of the 
fibroblast growth factor family and hepatocyte growth factor. J Cell Physiol. 1999 Dec;181(3):499-
506. 
 
21. Seale P, Rudnicki MA. A new look at the origin, function, and "stem-cell" status of muscle 
satellite cells. Dev Biol. 2000 Feb 15;218(2):115-24. 
 
22. Beauchamp JR, Heslop L, Yu DS, Tajbakhsh S, Kelly RG, Wernig A, Buckingham ME, Partridge 
TA, Zammit PS.  Expression of CD34 and Myf5 defines the majority of quiescent adult skeletal 
muscle satellite cells. J Cell Biol. 2000 Dec 11;151(6):1221-34. 
 
23. Cornelison DD, Wold BJ. Single-cell analysis of regulatory gene expression in quiescent and 
activated mouse skeletal muscle satellite cells. Dev Biol. 1997 Nov 15;191(2):270-83.  
 
24. Konig S, Hinard V, Arnaudeau S, Holzer N, Potter G, Bader CR, Bernheim L. Membrane 
hyperpolarization triggers myogenin and myocyte enhancer factor-2 expression during human 
myoblast differentiation.  J Biol Chem. 2004 Jul 2;279(27):28187-96. 
 
25. Skuk D, Tremblay JP. Myoblast transplantation: the current status of a potential therapeutic tool 
for myopathies. J Muscle Res Cell Motil 2003;24(4-6):285-300. 
 
26. Morgan JE, Pagel CN, Sherratt T, Partridge TA. Long-term persistence and migration of myogenic 
cells injected into pre-irradiated muscles of mdx mice. J Neurol Sci. 1993 Apr;115(2):191-200. 
 
27. Watt DJ, Morgan JE, Partridge TA.Use of mononuclear precursor cells to insert allogeneic genes 
into growing mouse muscles. Muscle Nerve. 1984 Nov-Dec;7(9):741-50. 
 
28. Morgan JE, Coulton GR, Partridge TA. Muscle precursor cells invade and repopulate freeze-killed 
muscles. J Muscle Res Cell Motil. 1987 Oct;8(5):386-96 
 
29. Miller RG, Sharma KR, Pavlath GK, Gussoni E, Mynhier M, Lanctot AM, Greco CM, Steinman 
L, Blau HM.Myoblast implantation in Duchenne muscular dystrophy: the San Francisco study. Muscle 
Nerve. 1997 Apr;20(4):469-78. 
 
30. Law PK, Goodwin TG, Fang Q, Hall TL, Quinley T, Vastagh G, Duggirala V, Larkin C, Florendo 
JA, Li L, Jackson T, Yoo TJ, Chase N, Neel M, Krahn T, Holcomb R. First human myoblast transfer 
therapy continues to show dystrophin after 6 years. Cell Transplant. 1997 Jan-Feb;6(1):95-100. 
 
31. Yoon PD, Kao RL, Magovern GJ. Myocardial regeneration. Transplanting satellite cells into 
damaged myocardium. Tex Heart Inst J. 1995;22(2):119-25.  
 45 
 
32. Murry CE, Wiseman RW, Schwartz SM, Hauschka SD. Skeletal myoblast transplantation for 
repair of myocardial necrosis. J Clin Invest. 1996 Dec 1;98(11):2512-23. 
 
33. Taylor DA, Atkins BZ, Hungspreugs P, Jones TR, Reedy MC, Hutcheson KA, Glower DD, Kraus 
WE. Regenerating functional myocardium: improved performance after skeletal myoblast 
transplantation. Nat Med. 1998 Aug;4(8):929-33.  
 
34. Ghostine S, Carrion C, Souza LC, Richard P, Bruneval P, Vilquin JT, Pouzet B, Schwartz K, 
Menasche P, Hagege AA. Long-term efficacy of myoblast transplantation on regional structure and 
function after myocardial infarction. Circulation. 2002 Sep 24;106(12 Suppl 1):I131-6.  
 
35. Hodgetts SI, Beilharz MW, Scalzo AA, Grounds MD. Why do cultured transplanted myoblasts die 
in vivo? DNA quantification shows enhanced survival of donor male myoblasts in host mice depleted 
of CD4+ and CD8+ cells or Nk1.1+ cells. Cell Transplant 2000;9(4):489-502. 
 
36. Smythe GM, Hodgetts SI, Grounds MD. Problems and solutions in myoblast transfer therapy. J 
Cell Mol Med. 2001 Jan-Mar;5(1):33-47.  
 
37. Qu Z, Balkir L, van Deutekom JC, Robbins PD, Pruchnic R, Huard J. Development of approaches 
to improve cell survival in myoblast transfer therapy. J Cell Biol. 1998 Sep 7;142(5):1257-67.  
 
38. Bouchentouf M, Benabdallah BF, Tremblay JP. Myoblast survival enhancement and 
transplantation success improvement by heat shock treatment in mdx mice. Transplantation. 2004 May 
15;77(9):1349-56. 
 
39. Guerette B, Skuk D, Celestin F, Huard C, Tardif F, Asselin I, Roy B, Goulet M, Roy R, Entman 
M, Tremblay JP. Prevention by anti-LFA-1 of acute myoblast death following transplantation. J 
Immunol. 1997 Sep 1;159(5):2522-31.  
 
40. Smythe GM, Grounds MD. Exposure to tissue culture conditions can adversely affect myoblast 
behavior in vivo in whole muscle grafts: implications for myoblast transfer therapy. Cell Transplant. 
2000 May-Jun;9(3):379-93.  
 
41. Wernig A, Irintchev A. "Bystander" damage of host muscle caused by implantation of MHC-
compatible myogenic cells. J Neurol Sci. 1995 Jun;130(2):190-6.  
 
42. Fink AL. Chaperone-mediated protein folding. Physiol Rev. 1999 Apr;79(2):425-49. 
 
43. Sharp FR, Massa SM, Swanson RA. Heat-shock protein protection. Trends Neurosci. 1999 
Mar;22(3):97-9. 
 
44. Jaattela M. Heat shock proteins as cellular lifeguards. Ann Med. 1999 Aug;31(4):261-71.  
 
45. Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded 
protein. Science. 2002 Mar 8;295(5561):1852-8. 
46. Barbe MF, Tytell M, Gower DJ, Welch WJ. Hyperthermia protects against light damage in the rat 
retina. Science. 1988 Sep 30;241(4874):1817-20.  
47. Kokubo Y, Matson GB, Derugin N, Hill T, Mancuso A, Chan PH, Wein-stein PR. Transgenic 
mice expressing human copper-zinc superoxide dismutase exhibit attenuated apparent diffusion 
coefficient reduction during reperfusion following focal cerebral ischemia. Brain Res. 2002 Aug 
23;947(1):1-8. 
 
 46 
48. Suzuki K, Murtuza B, Sammut IA, Latif N, Jayakumar J, Smolenski RT, Kaneda Y, Sawa Y, 
Matsuda H, Yacoub MH. Heat shock protein 72 enhances manganese superoxide dismutase activity 
during myocardial ischemia-reperfusion injury, associated with mitochondrial protection and apoptosis 
reduction. Circulation. 2002 Sep 24;106(12 Suppl 1):I270-6. 
 
49. Jayakumar J, Suzuki K, Sammut IA, Smolenski RT, Khan M, Latif N, Abunasra H, Murtuza B, 
Amrani M, Yacoub MH. Heat shock protein 70 gene transfection protects mitochondrial and 
ventricular function against ischemia-reperfusion injury. Circulation. 2001 Sep 18;104(12 Suppl 
1):I303-7. 
 
50. Jayakumar J, Suzuki K, Khan M, Smolenski RT, Farrell A, Latif N, Raisky O, Abunasra H, 
Sammut IA, Murtuza B, Amrani M, Yacoub MH. Gene therapy for myocardial protection: transfection 
of donor hearts with heat shock protein 70 gene protects cardiac function against ischemia-reperfusion 
injury. Circulation. 2000 Nov 7;102(19 Suppl 3):III302-6.  
 
51. Suzuki K, Sawa Y, Kaneda Y, Ichihara H, Shirakura R, Matsuda H. In vivo gene transfection with 
heat shock protein 70 enhances myocardial tolerance to ischemia-reperfusion injury in rat. J Cardiol. 
1998 Mar;31(3):187-188.  
 
52. Plumier JC, Krueger AM, Currie RW, Kontoyiannis D, Kollias G, Pagoula-tos GN. Transgenic 
mice expressing the human inducible Hsp70 have hippocampal neurons resistant to ischemic injury. 
Cell Stress Chaperones. 1997 Sep;2(3):162-7. 
 
53. Rea IM, McNerlan S, Pockley AG. Serum heat shock protein and anti-heat shock protein antibody 
levels in aging. Exp Gerontol. 2001 Feb;36(2):341-52. 
 
54. Pockley AG, Wu R, Lemne C, Kiessling R, de Faire U, Frostegard J. Circulating heat shock 
protein 60 is associated with early cardiovascular disease. Hypertension. 2000 Aug;36(2):303-7. 
 
55. Xu Q, Schett G, Perschinka H, Mayr M, Egger G, Oberhollenzer F, Willeit J, Kiechl S, Wick G. 
Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general 
population. Circulation. 2000 Jul 4;102(1):14-20. 
 
56. Dybdahl B, Wahba A, Lien E, Flo TH, Waage A, Qureshi N, Sellevold OF, Espevik T, Sundan A. 
Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling 
through toll-like receptor-4. Circulation. 2002 Feb 12;105(6):685-90. 
 
57. Xanthoudakis S, Nicholson DW. Heat-shock proteins as death determinants. Nat Cell Biol. 2000 
Sep;2(9):E163-5. 
 
58. Shi Y, Thomas JO. The transport of proteins into the nucleus requires the 70-kilodalton heat shock 
protein or its cytosolic cognate. Mol Cell Biol. 1992 May;12(5):2186-92.  
 
59. Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, Tailor P, Morimoto RI, 
Cohen GM, Green DR. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of 
procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol. 2000 Aug;2(8):469-75. 
 
60. Saleh A, Srinivasula SM, Balkir L, Robbins PD, Alnemri ES. Negative regulation of the Apaf-1 
apoptosome by Hsp70. Nat Cell Biol. 2000 Aug;2(8):476-83.  
 
61. Williams RS, Thomas JA, Fina M, German Z, Benjamin IJ. Human heat shock protein 70 (hsp70) 
protects murine cells from injury during metabolic stress. J Clin Invest. 1993 Jul;92(1):503-8.  
 
62. Amici C, Giorgi C, Rossi A, Santoro MG. Selective inhibition of virus protein synthesis by 
prostaglandin A1: a translational block associated with HSP70 synthesis. J Virol. 1994 
Nov;68(11):6890-9.  
 47 
 
63. Mestril R, Chi SH, Sayen MR, Dillmann WH. Isolation of a novel inducible rat heat-shock protein 
(HSP70) gene and its expression during ischaemia/hypoxia and heat shock. Biochem J. 1994 Mar 
15;298 Pt 3:561-9.  
 
64. Hu Y, Benedict MA, Ding L, Nunez G.Role of cytochrome c and dATP/ATP hydrolysis in Apaf-
1-mediated caspase-9 activation and apoptosis. EMBO J. 1999 Jul 1;18(13):3586-95.  
 
65. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X.Cytochrome c 
and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. 
Cell. 1997 Nov 14;91(4):479-89. 
 
66. Park HS, Lee JS, Huh SH, Seo JS, Choi EJ. Hsp72 functions as a natural inhibitory protein of c-
Jun N-terminal kinase.EMBO J. 2001 Feb 1;20(3):446-56.  
 
67. Pandey P, Saleh A, Nakazawa A, Kumar S, Srinivasula SM, Kumar V, Weichselbaum R, Nalin C, 
Alnemri ES, Kufe D, Kharbanda S. Negative regulation of cytochrome c-mediated oligomerization of 
Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J. 2000 Aug 15;19(16):4310-
22.  
 
68. Bruey JM, Ducasse C, Bonniaud P, Ravagnan L, Susin SA, Diaz-Latoud C, Gurbuxani S, Arrigo 
AP, Kroemer G, Solary E, Garrido C. Hsp27 negatively regulates cell death by interacting with 
cytochrome c. Nat Cell Biol. 2000 Sep;2(9):645-52.  
69. Xanthoudakis S, Roy S, Rasper D, Hennessey T, Aubin Y, Cassady R, Tawa P, Ruel R, Rosen A, 
Nicholson DW. Hsp60 accelerates the maturation of pro-caspase-3 by upstream activator proteases 
during apoptosis. EMBO J. 1999 Apr 15;18(8):2049-56.  
70. Garrido C, Bruey JM, Fromentin A, Hammann A, Arrigo AP, Solary E. HSP27 inhibits 
cytochrome c-dependent activation of procaspase-9.FASEB J. 1999 Nov;13(14):2061-70.  
71. Samali A, Cai J, Zhivotovsky B, Jones DP, Orrenius S. Presence of a pre-apoptotic complex of 
pro-caspase-3, Hsp60 and Hsp10 in the mitochondrial fraction of jurkat cells. EMBO J. 1999 Apr 
15;18(8):2040-8.  
72. Bellmann K, Burkart V, Bruckhoff J, Kolb H, Landry J.p38-dependent enhancement of cytokine-
induced nitric-oxide synthase gene expression by heat shock protein 70. J Biol Chem. 2000 Jun 
16;275(24):18172-9.  
73. Kim YM, de Vera ME, Watkins SC, Billiar TR. Nitric oxide protects cultured rat hepatocytes from 
tumor necrosis factor-alpha-induced apoptosis by inducing heat shock protein 70 expression. J Biol 
Chem. 1997 Jan 10;272(2):1402-11.  
74. Garcia-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G.Papapetropoulos A, Sessa WC. 
Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature. 1998 Apr 
23;392(6678):821-4.  
75. Bluhm WF, Martin JL, Mestril R, Dillmann WH. Specific heat shock proteins protect microtubules 
during simulated ischemia in cardiac myocytes. Am J Physiol. 1998 Dec;275(6 Pt 2):H2243-9.  
76. Loktionova SA, Ilyinskaya OP, Kabakov AE. Early and delayed tolerance to simulated ischemia in 
heat-preconditioned endothelial cells: a role for HSP27. Am J Physiol. 1998 Dec;275(6 Pt 2):H2147-
58.  
 48 
77. Panjwani N, Akbari O, Garcia S, Brazil M, Stockinger B. The HSC73 molecular chaperone: 
involvement in MHC class II antigen presentation. J Immunol. 1999 Aug 15;163(4):1936-42. 
78. Wells AD, Rai SK, Salvato MS, Band H, Malkovsky M. Hsp72-mediated augmentation of MHC 
class I surface expression and endogenous antigen presentation. Int Immunol. 1998 May;10(5):609-17. 
79. Wallin RP, Lundqvist A, More SH, von Bonin A, Kiessling R, Ljunggren HG. Heat-shock proteins 
as activators of the innate immune system. Am J Physiol Cell Physiol. 2004 Apr;286(4):C739-44. 
80. Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, Koo GC, Calderwood 
SK. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its 
dual role as a chaperone and cytokine. Nat Med. 2000 Apr;6(4):435-42. 
 
81. Ciupitu AM, Petersson M, O'Donnell CL, Williams K, Jindal S, Kiessling R, Welsh RM. 
Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 
results in protective antiviral immunity and specific cytotoxic T lymphocytes. J Exp Med. 1998 Mar 
2;187(5):685-91. 
 
82. Blachere NE, Li Z, Chandawarkar RY, Suto R, Jaikaria NS, Basu S, Udono H, Srivastava PK. 
Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T 
lymphocyte response and tumor immunity.J Exp Med. 1997 Oct 20;186(8):1315-22. 
 
83. Baroffio A, Aubry JP, Kaelin A, Krause RM, Hamann M, Bader CR. Purification of humaan 
muscle satellite cells by flow cytometry. Muscle Nerve 1993; 16(5): 498-505. 
  
84.Cudre-Mauroux C, Occhiodoro T, Konig S, Salmon P, Bernheim L, Trono D. Lentivector-mediated  
transfer of Bmi-1 and telomerase in muscle satellite cells yields a duchenne myoblast cell line with 
long-term genotypic and phenotypic stability. Hum Gene Ther. 2003 Nov 1;14(16):1525-33. 
 
85. Proskuryakov SY, Konoplyannikov AG, Gabai VL. Necrosis: a specific form of programmed cell 
death? Exp Cell Res. 2003 Feb 1;283(1):1-16.  
 
86. Skuk D, Caron NJ, Goulet M, Roy B, Tremblay JP. Resetting the problem of cell death following 
muscle-derived cell transplantation: detection, dynamics and mechanisms. J Neuropathol Exp Neurol. 
2003 Sep;62(9):951-67.  
 
87. Wang Y, Knowlton AA, Christensen TG, Shih T, Borkan SC. Prior heat stress inhibits apoptosis in 
adenosine triphosphate-depleted renal tubular cells. Kidney Int. 1999 Jun;55(6):2224-35.  
 
88. Chen YC, Lin-Shiau SY, Lin JK. Involvement of heat-shock protein 70 and P53 proteins in 
attenuation of UVC-induced apoptosis by thermal stress in hepatocellular carcinoma cells. Photochem 
Photobiol. 1999 Jul;70(1):78-86.  
 
89. Jaattela M, Wissing D, Bauer PA, Li GC. Major heat shock protein hsp70 protects tumor cells 
from tumor necrosis factor cytotoxicity. EMBO J. 1992 Oct;11(10):3507-12. 
 
90. Yamashita N, Hoshida S, Nishida M, Igarashi J, Taniguchi N, Tada M, Kuzuya T, Hori 
M. Heat shock-induced manganese superoxide dismutase enhances the tolerance of cardiac 
myocytes to hypoxia-reoxygenation injury. J Mol Cell Cardiol. 1997 Jul;29(7):1805-13.  
      
 
 
 
